Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06588803 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Long-term Follow-up Study Evaluating Intravenous Injection of EXG001-307 in Patients With Type 1 SMA

StatusEnrolling by Invitation
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Enrolling by Invitation Start date: Sep 10, 2024 to Mar 2025 · Study sites: 0 to 1 · Study description shortened, about 6 words · 1 morev2 Show 4 more changesShow less
    • Start date: Sep 10, 2024 to Mar 2025
    • Study sites: 0 to 1
    • Study description shortened, about 6 words
    • Eligibility criteria shortened, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
An Open-label, Long-term Follow-Up Study to Evaluate the Safety and Tolerability of Gene Therapy with EXG001-307 in SMA1 patients ,who joined the parent study (EXG001-307-102)
Trial Details
NCT Number NCT06588803
Lead Sponsor Guangzhou Jiayin Biotech Ltd
Conditions Spinal Muscular Atrophy
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov